0000950170-24-022485.txt : 20240228
0000950170-24-022485.hdr.sgml : 20240228
20240228194157
ACCESSION NUMBER: 0000950170-24-022485
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240227
FILED AS OF DATE: 20240228
DATE AS OF CHANGE: 20240228
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: VAN NOSTRAND ROBERT L
CENTRAL INDEX KEY: 0001225198
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36274
FILM NUMBER: 24698167
MAIL ADDRESS:
STREET 1: C/O ACHILLION PHARMACEUTICALS, INC.
STREET 2: 300 GEORGE STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06511
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Intra-Cellular Therapies, Inc.
CENTRAL INDEX KEY: 0001567514
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 364742850
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 430 EAST 29TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10016
BUSINESS PHONE: 212-923-3344
MAIL ADDRESS:
STREET 1: 430 EAST 29TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10016
FORMER COMPANY:
FORMER CONFORMED NAME: Oneida Resources Corp.
DATE OF NAME CHANGE: 20130122
4
1
ownership.xml
4
X0508
4
2024-02-27
0001567514
Intra-Cellular Therapies, Inc.
ITCI
0001225198
VAN NOSTRAND ROBERT L
C/O INTRA-CELLULAR THERAPIES, INC.
430 EAST 29TH STREET
NEW YORK
NY
10016
true
false
false
false
false
Common Stock
2024-02-27
4
M
false
20000
18.56
A
29611
D
Common Stock
2024-02-27
4
S
false
9651
72.71
D
19960
D
Common Stock
2024-02-27
4
S
false
10349
73.14
D
9611
D
Stock Option (right to buy)
18.56
2024-02-27
4
M
false
20000
0.00
D
2024-03-21
Common Stock
20000
0
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.0016 to $73.00, inclusive. The reporting person undertakes to provide to the Issuer, any secuirty holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.0026 to $73.42, inclusive. The reporting person undertakes to provide to the Issuer, any secuirty holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
This option was granted on March 21, 2014 and will expire on March 21, 2024. All shares underlying this option have vested.
/s/ Lawrence J. Hineline, Attorney-in-fact
2024-02-28